All In Biotech

Drug Trial Radar · NCT01973790

Phase III, Long-term, Open-label Safety Study of Z-338

A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia

Last checked: Nov 19, 2026Latest source record: Jun 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Mar 2014

Primary completion

Nov 2016

Study completion Apr 2017

Sponsor

Lead sponsor
Zeria PharmaceuticalIndustry
Sponsor type
Industry
First posted
Nov 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.

Conditions

  • Dyspepsia

Interventions

  • Z-338Drug

    100mg TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. General safety endpointsTime frame: up to 58 weeks

Locations

36 sites in 10 countries. Site status is shown where the registry gives one.

  • Zeria Investigative site

    Leuven, Belgium

  • Zeria Investigative Site

    Plovdiv, Bulgaria

  • Zeria Investigative Sites

    Sofia, Bulgaria

  • Zeria Investigative site

    Varna, Bulgaria

  • Zeria Invetigative Site

    Liepāja, Latvia

  • Zeria Investivgative SIte

    Limbaži, Latvia

  • Zeria Investigative Sites

    Riga, Latvia

  • Zeria Investigative Site

    Alytus, Lithuania

  • Zeria Investigative Sites

    Kaunas, Lithuania

  • Zeria Investigative Site

    Klaipėda, Lithuania

  • Zeria Investigative Site

    Vilnius, Lithuania

  • Zeria Investigative Site

    Brasov, Romania

  • Zeria Investigative Sites

    Bucharest, Romania

  • Zeria Investigative Sites

    Cluj-Napoca, Romania

  • Zeria Investigative Site

    Sibiu, Romania

  • Zeria Investigative Site

    Târgu Mureş, Romania

  • Zeria Investigative Sites

    Timișoara, Romania

  • Zeria Investigative Site

    Kazan', Russia

  • Zeria Investigative Site

    Ryazan, Russia

  • Zeria Investigative Site

    Saratov, Russia

  • Zeria Investigative Site

    Yaroslavl, Russia

  • Zeria Investigative sites

    Bratislava, Slovakia

  • Zeria Investigative sites

    Košice, Slovakia

  • Zeria Investigative Site

    Malacky, Slovakia

  • Zeria Investigative Site

    Martin, Slovakia

  • Zeria Investigative Site

    Nitra, Slovakia

  • Zeria Investigative Site

    Prešov, Slovakia

  • Zeria Investigative Site

    Trnava, Slovakia

  • Zeria Investigative Site

    Gothenburg, Sweden

  • Zeria Investigative Sites

    Stockholm, Sweden

  • Zeria Investigative Site

    Dnipropetrovsk, Ukraine

  • Zeria Investigative Site

    Kyiv, Ukraine

  • Zeria Investigative Site

    Vinnytsia, Ukraine

  • Zeria Investigative site

    Barnstaple, United Kingdom

  • Zeria Investigative site

    Bath, United Kingdom

  • Zeria Investigative Site

    Royal Leamington Spa, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.